KALA BIO (KALA) Expected to Post Earnings on Tuesday

KALA BIO (NASDAQ:KALA) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($6.00) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

KALA BIO (NASDAQ:KALA) last released its earnings results on Wednesday, August 19th. The company reported ($21.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($15.32).

KALA BIO Price Performance

Shares of KALA traded up $0.00 during mid-day trading on Tuesday, hitting $0.17. The stock had a trading volume of 106,121 shares, compared to its average volume of 549,629. The firm has a market cap of $3.31 million, a P/E ratio of -0.01 and a beta of -2.40. The business has a fifty day moving average price of $0.43 and a 200-day moving average price of $6.89. KALA BIO has a 52 week low of $0.11 and a 52 week high of $95.50.

Analysts Set New Price Targets

KALA has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a report on Monday, September 21st. Wall Street Zen upgraded shares of KALA BIO from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

KALA BIO Company Profile

KALA BIO, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation.

KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly.